Kisspeptin: what the evidence shows

What the human research shows

An honest C: the physiology is real and reproducible, but the clinical studies are single-centre, small, mostly single-dose, and mostly measure hormones or brain scans rather than outcomes people care about. The 'research' vials sold online have nothing to do with these trials.

Evidence profile0–5

Metabolic & weight—0.0
Cardiovascular—0.0
Muscle & growth—0.0
Healing & repair—0.0
Neuro & sleep—0.0
Immune & inflammation—0.0
Sexual & hormonalB3.5
Skin & appearance—0.0
Ageing & longevity—0.0

Each score is confidence × effect size, taken from the best-evidenced benefit in that domain: the grade (A–D) sets the confidence, the measured effect sets the size. Hover a domain to see the outcomes behind it. Adverse effects are excluded and listed separately below.

Outcome	Grade	Effect size	Human studies	Where the evidence comes from
LH and testosterone release	BProbable	Large	Many small studies	Single doses of kisspeptin-10 or -54 raise LH within 30 minutes in healthy men and women — one of the most reproducible findings in human neuroendocrinology. Continuous exposure desensitises the response.1
IVF egg maturation trigger	CWeak	Moderate	2 phase 2 trials	Kisspeptin-54 as the final maturation trigger in 53 and then 60 women at high risk of ovarian hyperstimulation: live births achieved with no cases of severe OHSS. Not compared head-to-head with standard triggers at scale.2
Sexual desire (women with HSDD)	CWeak	Small	1 crossover RCT (n=32)	Two-visit double-blind crossover in 32 premenopausal women: kisspeptin infusion increased activation in sexual-processing brain regions on fMRI and reduced sexual aversion scores. A mechanism study, not a treatment trial.3
Sexual desire and arousal (men with HSDD)	CWeak	Small	1 crossover RCT (n=32)	Same design in 32 men: increased sexual-brain activation and a modest increase in penile tumescence to erotic stimuli. Single infusion; no data on repeated use.4
Safetyadverse	CWeak	Not measurable	Small studies	No side effects reported in the HSDD trials; the fertility studies reported no severe OHSS. Nothing is known about repeated self-administration.3 4

AMultiple good human trials, consistentBSome human trials, mostly consistentCFew or weak human studiesDAnimal or anecdotal onlyeffect size · red = adverse

Literature searched to 3 September 2026. Human studies only; animal and cell work informs the mechanism section and nothing else.

Registered trials

ClinicalTrials.gov lists 20 interventional studies naming Kisspeptin as an intervention — 13 completed, 4 recruiting, and 5 with results posted to the registry.

A registration is not a result. Anyone can register a study, and many never report — so this list shows what has been attempted, not what has been shown. The graded evidence above is the answer to whether something works.

Study	Phase	Status	Participants	Sponsor	Results
The Use of the Hormone Kisspeptin in 'in Vitro Fertilisation' (IVF) TreatmentNCT01667406 · started Jun 2012	Phase 2	Completed	175	Imperial College London	Posted
Administration of Kisspeptin in Patients With HyperprolactinemiaNCT02956447 · started Nov 2017	Phase 2	Completed	36	Massachusetts General Hospital	Posted
Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic HypogonadismNCT04648969 · started May 2019	Phase 2	Completed	18	Stephanie B. Seminara, MD	Posted
Recall by Genotype: Neuropeptide StimulationNCT05901467 · started Oct 2023	Phase 1	Terminated	16	Stephanie B. Seminara, MD	Posted
Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Oral Glucose Tolerance TestNCT04958109 · started Oct 2021	Phase 1	Completed	16	Massachusetts General Hospital	Posted
Link Between the Sensitivity of Kisspeptin Signalling and Pubertal Onset in Boys.NCT03286517 · started Jun 2014	Phase 3	Completed	30	Ghulam Nabi	None
Age-dependent Changes in the Responsiveness of Hypothalamic Pituitary Gonadal Axis in MenNCT03315325 · started Aug 2014	Phase 3	Completed	15	Quaid-e-Azam University	None
KP-10 and Insulin Secretion in MenNCT03771326 · started Oct 2013	Phase 3	Completed	14	Quaid-e-Azam University	None

12 further studies are registered. Participant counts marked * are the sponsor's estimate, not a final enrolment. Source: ClinicalTrials.gov, read directly from the registry and refreshed weekly.

What it is

A family of peptides encoded by the KISS1 gene — the full 54-amino-acid form and shorter fragments such as kisspeptin-10 — acting on the KISS1R receptor on GnRH neurons. Loss-of-function mutations cause absent puberty, which is how its role was discovered in 2003.

Almost all the human work comes from one group, at Imperial College London, using intravenous or subcutaneous infusions in a research setting. No company has taken a kisspeptin product through phase 3.

How it is thought to work

Kisspeptin neurons in the hypothalamus are the master switch for GnRH pulses. A dose produces a pulse of LH (and, in men, testosterone) about half an hour later; because the system desensitises, continuous dosing switches the axis off — the same paradox exploited by GnRH agonists.

Its receptors are also found in limbic brain regions involved in sexual and emotional processing, which is the rationale for the HSDD studies.

What is still unknown

Whether any of the mechanistic findings translate into a treatment that works over weeks.
Effects of repeated dosing on the reproductive axis outside a trial.
The purity and identity of anything sold as kisspeptin online.

The molecule and how long it lasts

Identity

Formula: C63H83N17O14
Molecular weight: 1302.4 g/mol
CAS number: 374675-21-5
PubChem: CID 25240297

Kisspeptin-10, the fragment used in human studies

PubChem record, read 23 September 2026.

Pharmacokinetics

Route: Intravenous (healthy men)
Half-life: About 4 minutes (kisspeptin-10, intravenous); kisspeptin-54 about six times longer

From a published human pharmacokinetic study: Jayasena CN, et al. Direct comparison of the effects of intravenous kisspeptin-10, kisspeptin-54 and GnRH on gonadotrophin secretion in healthy men. Hum Reprod 2015

Regulatory status

European Union

Unauthorised medicinal product

No marketing authorisation. Supplying it for human use is an offence under national medicines law.

United States

Not approved; compounding barred

Kisspeptin-10 remains in Category 2 of the FDA's 503A list (significant safety risks) as of April 2026 — it may not be compounded.

United Kingdom

Unlicensed medicine

Used only in academic trials; supply for human use is an offence.

Australia

Schedule 4, unapproved

Prescription-only substance not on the ARTG.

Canada

Not authorised

No DIN; selling it is illegal.

Sport (WADA)

Prohibited at all times (males)

S2.2.1: 'kisspeptin and its agonist analogues', prohibited in males as an LH/testosterone releaser.

Questions people actually ask

Does kisspeptin increase testosterone?

Acutely, yes: a single dose reliably raises LH and then testosterone in men within an hour or two. Repeated or continuous exposure desensitises the axis and can lower it. That acute effect is why it is banned for male athletes.

Is kisspeptin a treatment for low libido?

Not yet. Two single-dose crossover trials in 32 women and 32 men showed increased sexual-brain activation and reduced sexual aversion. They were designed to test a mechanism, not to treat anyone, and no trial has tested weeks of use.

Is kisspeptin used in IVF?

In research. Phase 2 trials used kisspeptin-54 as the trigger for final egg maturation in women at high risk of ovarian hyperstimulation, with live births and no severe OHSS. It is not a standard-of-care trigger.

One page per claimed effect

BDoes Kisspeptin help with LH and testosterone release?Many small studies
CDoes Kisspeptin help with IVF egg maturation trigger?2 phase 2 trials
CDoes Kisspeptin help with sexual desire?1 crossover RCT (n=32)
CDoes Kisspeptin help with sexual desire and arousal?1 crossover RCT (n=32)
CHow common is safety with Kisspeptin?Small studies

References

1
Dhillo WS, et al. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males; and subsequent physiology studies from the same group.J Clin Endocrinol Metab, 2005 onwardThe foundational human dosing studies.
2
Abbara A, et al. Efficacy of kisspeptin-54 to trigger oocyte maturation in women at high risk of OHSS during IVF therapy.J Clin Endocrinol Metab, 2015Phase 2; follows Jayasena 2014 (n=53).
3
Thurston L, et al. Effects of kisspeptin administration in women with hypoactive sexual desire disorder: a randomized clinical trial.JAMA Netw Open, 2022; DOI 10.1001/jamanetworkopen.2022.3613132 premenopausal women, double-blind crossover.
4
Mills EG, et al. Effects of kisspeptin on sexual brain processing and penile tumescence in men with hypoactive sexual desire disorder: a randomized clinical trial.JAMA Netw Open, 2023; DOI 10.1001/jamanetworkopen.2022.5431332 men, double-blind crossover.

Change log

2026-09-03Initial publication from the Imperial College physiology, IVF and HSDD trials.